Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/

Accepted 2024-04-01 00:00:00 ET · period of report 2024-04-01 · accession 0000950170-24-039590 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2024-04-01	2024-04-01	DNTH	Kiselak Tomas	Dir, 10%	J - Other	—	0	0	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-04-01	J	A	58,857	—	2,700,691	I By Fairmount Healthcare Fund II LP	—	—	(F1) On April 1, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). (F3) Fairmount is the investment manager for Fund II. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
2	Common	Common Stock	2024-04-01	J	D	58,857	—	0	I By Fairmount Healthcare Fund LP	—	—	(F1) On April 1, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). (F2) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund I. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.